SecBot SecBot
Institutional Cluster

XERS

Xeris Biopharma Holdings, Inc.
BULLISH
Impact 4/10
Horizonweeks Processed5mo ago
Institutional cluster: 6 buyers, 3 sellers (mixed)
Actionable Insight ▲ Bullish

The cluster is small in absolute dollars but directionally consistent, 6 funds all adding while 3 trimming negligibly. D.E. Shaw's quant models finding XERS attractive is a positive signal, but the $2.1M net buy on a micro-cap biotech with recent insider selling suggests moderate conviction, not transformative. Monitor for pipeline catalysts (FDA decisions, trial readouts) that could explain the shared thesis and provide a near-term trigger.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.79
T+0 close · Jun 12, 2026 · via day close
Latest settled
+24.89%
T+60 · $8.48
Vs SPY
+21.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $6.79entry
  2. T+1 · 5mo ago +1.33%α −0.44% · $6.88
  3. T+5 · 5mo ago +2.36%α +1.68% · $6.95
  4. T+20 · 4mo ago +22.83%α +21.05% · $8.34
  5. T+60 · 2mo ago +24.89%α +21.63% · $8.48

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Six institutional buyers accumulated $3.5M in XERS shares during 2024-Q3, led by quant hedge fund D.E. Shaw which added $1.6M to its position (now $2.8M), while three asset managers trimmed $82K. The buying is concentrated and net-positive at $2.1M, but absolute dollar amounts are micro-cap scale. Insider selling of $311K over the prior 30 days adds a cautionary note.

Key Financial Metrics

Direction
accumulating
Buy Value
$3.5M
Sell Value
$82.1K
Net Flow
$2.1M

Institutional Positions

Net institutional flow: $2.1M

▲ Buyers (6)

InstitutionActionChangePosition ValueValue Δ
D.E. ShawADD+90.1%$2.8M$1.6M
Legal & General GroupDOUBLED+1317.9%$601.0K$567.0K
Corient Private WealthADD+53.7%$72.0K$35.0K

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
MarinerTRIM-54.8%$151.0K-$64.5K
Metlife Investment ManagementTRIM-28.4%$186.0K-$17.2K
Lazard Asset ManagementTRIM-40.5%$1.0K-$353.00

Key Facts

  • 6 buyers accumulated $3.5M vs 3 sellers trimmed $82K, net $2.1M into XERS in Q3 2024
  • D.E. Shaw (quant/hedge fund) was the dominant buyer: added 467K shares, growing position to $2.8M from $1.2M
  • Legal & General Group nearly 14x'd its position (+1318%) to $601K, Corient Private Wealth added 54% to $72K
  • Sellers were small-scale trims: Mariner ($65K cut), Metlife ($17K cut), Lazard ($353 cut)
  • Prior 30-day insider activity: 3 sells totaling $311K, mild bearish signal at the security level
  • Analyst consensus is 85% bullish (5 Strong Buy, 6 Buy, 2 Hold) on this clinical-stage biotech

Financial Impact

Net institutional inflow of approximately $2.1M into XERS stock during Q3 2024, with D.E. Shaw and Legal & General accounting for 93% of buying. Total disclosed institutional positions now ~$3.5M across 6 funds.

institutional ownershipfloat held by tracked funds

Risk Factors

  • Absolute dollar amounts are tiny ($3.5M aggregate), may reflect routine rebalancing, not conviction
  • 13F data is 45+ days stale; these positions may have been fully unwound since quarter-end
  • Recent insider selling ($311K/30d) conflicts with institutional buying signal
  • XERS is a clinical-stage biotech with no approved revenue, binary pipeline risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-XERS-2024-Q3

Track record

25 reports on XERS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 settles Dec 8
  2. Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 settles Dec 4
  4. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 settles Dec 4
  5. Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 settles Dec 4
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 settles Dec 2
  7. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 settles Dec 1
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 settles Nov 30
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 ▲ +69.09% +70.36% vs SPY
  10. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 ▲ +5.73% +8.19% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026